Aldeyra Therapeutics Receives Complete Response Letter From FDA For NDA Of ADX-2191
Portfolio Pulse from Bill Haddad
Aldeyra Therapeutics has received a Complete Response Letter from the FDA for the New Drug Application (NDA) of ADX-2191, indicating that the FDA has completed its review but is not approving the drug at this time.
June 21, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aldeyra Therapeutics' stock may be negatively impacted by the FDA's Complete Response Letter for the NDA of ADX-2191.
The FDA's Complete Response Letter indicates that the agency has completed its review of ADX-2191 but is not approving the drug at this time. This may lead to delays in the drug's approval process and potential revenue generation, which could negatively impact Aldeyra Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100